Remove 2024 Remove Biotechnology Remove Mergers and acquisition activities
article thumbnail

Pharmaceutical Outsourcing Evolution: The Rise of Clinical Peripheral Services

Frost & Sullivan

billion in 2024, is projected to grow at a CAGR of 10.7%, reaching $122.13 This article explores the key trends, market drivers, and emerging opportunities in the pharmaceutical clinical contract peripheral services market from 2024 to 2030. The global CRO industry, valued at $66.39 billion by 2030.

article thumbnail

JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology

Frost & Sullivan

Key Trends and Growth Opportunities Focus on Mergers & Acquisitions (M&A) Driving Industry Consolidation M&A activity emerged as a dominant theme at JPM 2025, with deals exceeding $18 billion announced during the conference. billion acquisition of Scorpion Therapeutics , adding a promising PI3K inhibitor program.